Your guide to a public health crisis that’s likely to get worse.
Academic rigor, journalistic flair
Articles on Big Pharma
Displaying 61 - 80 of 113 articles
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies’ own finances.
In an era when opinion often trumps evidence in public health issues, it’s time to support and invest in evidence-based medicine to protect the public from dangerous, poorly informed beliefs.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Drug companies funded more than 116,000 educational events for doctors over four years. Now you can find out exactly which companies footed the bills and how much they paid.
More of us are labelled as sick with the constantly changing diagnostic cut-offs for diseases. Now an international expert panel has drafted a list of things to consider before setting new thresholds.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
We have barely begun to tap into the pharmaceutical potential of the most diverse animals of all.
Children’s cancer is a rare disease, which means the market is small and pharmaceutical companies have few incentives to develop drugs for these cancers.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Feel-good fudges designed to boost staff morale are giving way to tangible projects which can be reported to shareholders.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company’s products.
What will happen to immigration, wages and the economy has been discussed at length. But the price of drugs may also be affected.
The sources of the opioid epidemic are complex, but one powerful motivator has been the pursuit of profit.
The lack of transparency and accountability found in the hedge fund world is increasingly finding a home in the pharmaceutical sector, where more people care.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
Pharmaceutical companies aim to make a profit, but it took an industry insider to blow the whistle on some exorbitant drug costs the NHS was paying.
This project offers the tantalising possibility that plants containing drugs, such as agents to treat HIV, could be farmed on a small scale at low cost by communities that need them most.
Clinton, who named drug companies among her enemies in this week’s debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, Bond University
-
Professor of Bioethics, Macquarie University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Chief Scientist, Center for Bioethics and Humanities and Professor of Medicine and Public Health, University of Colorado Anschutz Medical Campus
-
Associate Professor Politics and Policy Studies, Deakin University
-
Health activist, Medreach Pty Ltd., Bond University
-
Macquarie University Research Fellow, Macquarie University
-
Lecturer in Accounting & Management, Lancaster University
-
HERA Program Director - Health Workforce Optimisation Centre for the Business & Economics of Health, The University of Queensland
-
PhD Candidate, Swinburne University of Technology
-
Adjunct Professor, Australian Centre for Health Law Research, School of Law, Queensland University of Technology
-
Associate professor, University of Sydney
